Mp46-03 Preservation of Sexual Function With Optilume: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology III (MP46)1 May 2024MP46-03 PRESERVATION OF SEXUAL FUNCTION WITH OPTILUME: A NOVEL TREATMENT FOR LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA Olivia R. Copelan, Steven A. Kaplan, and Kevin T. McVary Olivia R. CopelanOlivia R. Copelan , Steven A. KaplanSteven A. Kaplan , and Kevin T. McVaryKevin T. McVary View All Author Informationhttps://doi.org/10.1097/01.JU.0001008668.53858.38.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Many treatments for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) have negative effects on sexual function. Data from a prospective, randomized, double-blind, sham-controlled study evaluating the Optilume BPH Catheter System was evaluated to determine the impact of treatment with this novel technology on sexual function. Optilume BPH is a novel minimally invasive surgical therapy (MIST) that combines mechanical dilation with delivery of paclitaxel. METHODS: One hundred forty eight subjects were randomized in a 2:1 fashion to receive Optilume BPH or Sham (100:48). Baseline measures included assessments via the International Index of Erectile Function (IIEF) and Men's Sexual Health Questionnaire – Ejaculatory Dysfunction (MSHQ-EjD). Subjects were directly queried regarding existing or new diagnosis of erectile or ejaculatory dysfunction at the baseline visit. Symptoms were assessed via the International Prostate Symptom Score (IPSS). RESULTS: Subject demographics were similar between the Optilume and Sham arms, and no difference noted in the sexually active versus non-sexually active subjects. Subgroup analysis evaluated sexual function outcomes based on baseline erectile dysfunction (ED) and ejaculatory dysfunction (EjD) (Figure 1A , 1B). IIEF-EF and MSHQ-EjD were not different from sham at 3, 6, or 12 months. Change in IIEF-EF remained consistent across all levels of baseline ED severity. Improvement in LUTS at 12 months in the Optilume arm was also consistent across subgroups, with a 46% and 51% improvement in subjects with and without ED, respectively. Semen quality parameters did not significantly change post-procedure. Paclitaxel was detected in semen in most subjects tested at 30 days and 3 months. Paclitaxel concentration in semen decreased over time, nearing the limit of quantitation by 6 months. CONCLUSIONS: Treatment with Optilume BPH resulted in significant symptom relief while preserving erectile and ejaculatory function. These results offer support for the use of Optilume BPH in patients seeking treatment for LUTS secondary to BPH who are concerned with preserving sexual function. Download PPT Source of Funding: Urotronic © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e753 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Olivia R. Copelan More articles by this author Steven A. Kaplan More articles by this author Kevin T. McVary More articles by this author Expand All Advertisement PDF downloadLoading ...